Vorinostat for the Treatment of Bullous Pemphigoid in the Setting of Advanced, Refractory Cutaneous T-Cell Lymphoma

Archives of Dermatology
doi 10.1001/archdermatol.2009.229
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Medical Association (AMA)

Related search

Benefits of Vorinostat in Treating Advanced Cutaneous T-Cell Lymphoma

Oncology & Hematology Review (US)
2009English

Trends in the Treatment of Cutaneous T-Cell Lymphoma &Ndash; Critical Evaluation and Perspectives on Vorinostat

Blood and Lymphatic Cancer: Targets and Therapy
2012English

Bullous Pemphigoid Associated With Mantle Cell Lymphoma

Archives of Dermatology
2004English

Vorinostat Approved in Japan for Treatment of Cutaneous T-Cell Lymphomas: Status and Prospects

OncoTargets and Therapy
OncologyPharmacology
2012English

Bullous Pemphigoid Associated With Cemiplimab Therapy in a Patient With Locally Advanced Cutaneous Squamous Cell Carcinoma

JAAD Case Reports
Dermatology
2020English

Treatment of Cutaneous T-Cell Lymphoma: An Update

Journal of the American Osteopathic Association, The
MedicineAlternative MedicineComplementary
1993English

Increasing Evidence for Omalizumab in the Treatment of Bullous Pemphigoid

JAAD Case Reports
Dermatology
2020English

Orphan Designation: Mogamulizumab, Treatment of Cutaneous T-Cell Lymphoma

Case Medical Research
2019English

676 Exploring Novel Therapeutic Targets in the Treatment of Cutaneous T-Cell Lymphoma

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy